2014 Project Grants


Successful Project Grant funding

24 October 2013

Congratulations to CTC researchers and collaborators who have been successfully awarded over $11 million in National Health and Medical Research Council (NHMRC) and Cancer Australia grants. Research projects in diabetes, neonatal disorders, health economics and cancer were funded. Results of grant applications to Cancer Council will be released later this year.

Read more about the grants awarded here:

BIOSTATISTICS

A/Prof Sarah Lord will be working with Prof Karen Canfell at the University of New South Wales who was funded $674 128 for the evaluation of outcomes and cost-effectiveness of implementing next generation human papillomavirus (HPV) vaccination and associated primary HPV-based cervical cancer screening strategies in Australia.

CTC biostatistician Elizabeth Barnes will be collaborating with  A/Prof Lyndal Trevena who was funded $424 115 to work on the study: Should I take low dose aspirin? The 'Optimise' decision aid study.

CARDIOVASCULAR AND DIABETES

Prof Alicia Jenkins and her group at the universities of Sydney and Melbourne were awarded $2 754 608 for the FAME1 trial which will evaluate the efficacy and safety of fenofibrate for protection against retinal damage in 450 adults with type 1 diabetes who have early diabetic retinopathy. Should study results prove positive, an existing, low-cost, well-tolerated treatment to reduce the personal and economic burden of the complications of type 1 diabetes will be established and can rapidly be translated into clinical practice worldwide.

Prof Jenkins will also be working alongside Martin Ng, awarded $609 505 on a project which is evaluating the protective effects of fenofibrate in diabetes-related susceptibility to ischaemia.

HEALTH ECONOMICS

Health economist Emily Callander is collaborating with A/Prof Vicki Flenady (Mater Medical Research Institute Limited) and her group on the trial: My Baby's Movements: A stepped wedged cluster randomised trial of maternal awareness and reporting of decreased foetal movements to reduce stillbirth.

NEONATAL

Prof Tarnow-Mordi and colleagues were awarded $2 636 507 for a trial evaluating whether iron deficiency anaemia of pregnancy should be treated with lactoferrin.

Dr Helen Liley and her group, which includes the CTC's Lisa Askie and Rachel O'Connell, were awarded $2 010 583 for a multicentre trial to determine whether high-dose erythropoietin plus hypothermia improves outcomes following hypoxic-ischemic encephalopathy at 2 years of age, compared to hypothermia alone.

ONCOLOGY

Prof Michael Friedlander and colleagues, including Rachel O'Connell, Katrin Sjoquist, Julie Martyn and Chee Lee, were awarded $394 745 for the Symptom Benefit clinical trial is addressing the important question of whether palliative chemotherapy improves symptoms in recurrent ovarian cancer patients using patient-reported outcomes.

Prof Andrew Davidson and colleagues, including Emily Callander, were awarded $487 974 for the NITRO clinical trial (an ALTG trial) which aims to corroborate recent evidence that transdermal nitroglycerin during first-line chemotherapy for advanced non-small-cell lung cancer leads to significant improvements in tumour response and survival.

These projects represent research which aim to improve health outcomes in Australia and around the world.